Correlation Between Esperion Therapeutics and Aligos Therapeutics

Can any of the company-specific risk be diversified away by investing in both Esperion Therapeutics and Aligos Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Esperion Therapeutics and Aligos Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Esperion Therapeutics and Aligos Therapeutics, you can compare the effects of market volatilities on Esperion Therapeutics and Aligos Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Esperion Therapeutics with a short position of Aligos Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Esperion Therapeutics and Aligos Therapeutics.

Diversification Opportunities for Esperion Therapeutics and Aligos Therapeutics

0.66

Correlation Coefficient

Esperion Therapeutics  Aligos Therapeutics

Poor diversification

The 3 months correlation between Esperion and Aligos is 0.66. Overlapping area represents the amount of risk that can be diversified away by holding Esperion Therapeutics and Aligos Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aligos Therapeutics and Esperion Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Esperion Therapeutics are associated (or correlated) with Aligos Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aligos Therapeutics has no effect on the direction of Esperion Therapeutics i.e., Esperion Therapeutics and Aligos Therapeutics go up and down completely randomly.

Pair Corralation between Esperion Therapeutics and Aligos Therapeutics

Given the investment horizon of 90 days Esperion Therapeutics is expected to generate 0.48 times more return on investment than Aligos Therapeutics. However, Esperion Therapeutics is 2.08 times less risky than Aligos Therapeutics. It trades about -0.12 of its potential returns per unit of risk. Aligos Therapeutics is currently generating about -0.29 per unit of risk. If you would invest  215.00  in Esperion Therapeutics on December 29, 2024 and sell it today you would lose (54.00) from holding Esperion Therapeutics or give up 25.12% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Esperion Therapeutics  vs.  Aligos Therapeutics

Esperion Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Esperion Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Aligos Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Aligos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Esperion Therapeutics and Aligos Therapeutics

The main advantage of trading using opposite Esperion Therapeutics and Aligos Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Esperion Therapeutics position performs unexpectedly, Aligos Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aligos Therapeutics will offset losses from the drop in Aligos Therapeutics' long position.

The idea behind Esperion Therapeutics and Aligos Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.